Axio BioPharma

Based in the US, Axio BioPharma, operates as a biotechnology company that focuses on providing high-throughput monoclonal antibody production and federated manufacturing data platforms for biotech, pharmaceutical and contract manufacturing companies. Founded in 2024, Axio BioPharma operates in the biotechnology sector, specializing in high-throughput monoclonal antibody production. In September 2026, Axio BioPharma raised USD 2. 4 mn in pre-seed funding from Elmstead Partners, Chisos Capital, and Chemical Angel Network, among other investors.

This funding will support initial deployments of Axio Lattice and the continued development of Rosetta, the ontology mapping layer of Axio Lattice. Axio BioPharma offers a specialized solution known as Axio Lattice, which facilitates seamless data connectivity between pharmaceutical sponsors and manufacturing partners, thus streamlining the tech transfer process. The platform integrates disparate data systems while ensuring that each company retains control over its underlying records, enabling real-time data matching. Axio's primary clientele includes pharmaceutical sponsors, contract development and manufacturing organizations (CDMOs), and technology partners involved in biologics development, particularly in North America and Europe.

The revenue model for Axio BioPharma is based on B2B transactions that foster ongoing partnerships with pharmaceutical companies and manufacturing entities. Clients engage with Axio Lattice through subscription agreements for data integration and management. Additionally, partnerships with manufacturers and technology developers enhance the revenue stream, with pricing structures accommodating diverse client needs through tiered subscriptions based on the scope of data integration required. The company plans to utilize the pre-seed funding to support initial deployments of Axio Lattice and further develop Rosetta, enhancing its capabilities in ontology mapping.